Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOWARD: Step Down Inhalers in COPD
NCT03527927Completed
- Sponsor
- Hywel Dda University Health Board
- Start
- May 2017
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of long-acting beta2-agonist + long-acting muscarinic antagonist in chronic obstructive pulmonary disease (COPD), sponsored by Hywel Dda University Health Board. Primary endpoint: Numbers maintained on dual bronchodilation at 12 months. Started May 2017; status: completed.
02
Drugs
long-acting beta2-agonist + long-acting muscarinic antagonist
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03527927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03527927.